Aripiprazole Tablet
Product Images NDC 71335-1893

Product Visual Gallery

This gallery contains 11 technical images submitted to the FDA as part of the official labeling for Aripiprazole (NDC 71335-1893). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bryant Ranch Prepack, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure1 (Figure1)

A pharmacokinetic chart titled 'Effect of Other Drugs on Aripiprazole' showing fold changes and 90% confidence intervals for Aripiprazole's AUC and Cmax when co-administered with various inhibitors, inducers, gastric acid blockers, and other drugs. The x-axis represents change relative to reference without interacting drug, ranging from 0.0 to 3.0.*

FDA Label Image

Figure2 (Figure2)

A chart titled 'Effect of Other Drugs on Aripiprazole' showing the fold change in Dehydro-Aripiprazole levels with 90% confidence intervals. The x-axis measures change relative to a reference without interacting drugs, ranging from 0 to 3. Various drugs are listed on the y-axis as CYP3A4 inhibitor (ketoconazole), CYP2D6 inhibitor (quinidine), CYP3A4 inducer (carbamazepine), gastric acid blockers (famotidine), and others (valproate, lithium, lorazepam). The chart depicts their impact on pharmacokinetic parameters AUC and Cmax of Aripiprazole.*

FDA Label Image

Figure3 (Figure3)

A horizontal forest plot chart showing the effect of Aripiprazole on various other drugs, with fold change and 90% confidence intervals relative to a reference without interacting drug. The chart includes drugs metabolized by CYP2D6, CYP2C9, 2C19, and UGT1A4, with endpoints such as AUC, Cmax, INR, and DMDRP plotted against a horizontal axis ranging from 0.5 to 3.0, representing change relative to reference.*

FDA Label Image

Figure4 (Figure4)

A pharmacokinetic chart titled 'Aripiprazole Fold Change and 90% CI' showing fold changes in AUC and Cmax for special populations including CYP2D6 metabolizer status, gender, age, hepatic impairment severity, and severe renal impairment, with error bars indicating confidence intervals versus reference values on a horizontal axis of change relative to reference from 0.5 to 3.0.*

FDA Label Image

Figure5 (Figure5)

A pharmacokinetic chart titled 'Dehydro-Aripiprazole Fold Change and 90% CI' showing fold changes in AUC and Cmax for various comparisons including CYP2D6 metabolizer status, gender, age groups, hepatic impairment severity, and severe renal impairment. The x-axis represents change relative to reference from 0.0 to 3.0, with data points and 90% confidence intervals depicted for each variable.*

FDA Label Image

Structure (Structure)

Chemical structure diagram of Aripiprazole, showing the molecular composition with labeled atoms of chlorine, nitrogen, oxygen, and carbon in the characteristic configuration.*

FDA Label Image

Camberlogo (Camber Logo)

FDA Label Image

Figure 6 (Figure 6)

This is a Kaplan-Meier curve displaying the proportion of subjects with relapse over time, comparing Aripiprazole and placebo groups. The x-axis represents days from randomization, and the y-axis shows the proportion with relapse. The chart includes numbers of subjects at risk for both groups at various time points.*

FDA Label Image

Figure 7 (Figure 7)

A Kaplan-Meier plot showing the proportion of subjects with relapse over days from randomization comparing Aripiprazole 5 mg tablets versus placebo. The x-axis represents days from randomization up to 182 days, and the y-axis shows the proportion with relapse from 0 to 1. A table below indicates the number of subjects at risk at various time points for both groups.*

FDA Label Image

Figure 8 (Figure 8)

A line plot showing the proportion of subjects with relapse over days from randomization for Aripiprazole and placebo groups. The x-axis represents days from 0 to 364, and the y-axis represents the proportion with relapse from 0.0 to 1.0. Two lines compare Aripiprazole (solid line) and placebo (dashed line). Below the x-axis, the number of subjects at risk over time is listed for both groups.*

FDA Label Image

Label (Lbl713351893)

Label for Aripiprazole 5 mg Tablet by Bryant Ranch Prepack, showing the nonproprietary name, strength, and dosage form. The label includes a comparison to Abilify 5 mg Tablet by Hetero Labs Limited, lot number 1523487, and storage instructions at room temperature (20°-25°C). It also displays a barcode and the NDC 71335-1893-1. The label states RX only and cautions to keep drugs out of reach of children.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.